

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA

**Talazoparib with enzalutamide for untreated hormone-
relapsed metastatic prostate cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

Yes. Age, race and gender reassignment were identified as potential equalities issues during scoping phase. Age, race and gender reassignment are protected under the Equality Act 2010.

The committee considered that some people with untreated hormone-relapsed metastatic prostate cancer may be older and from a Black African, Black Caribbean, or any other Black or Black British ethnic background. People from an Ashkenazi Jewish ethnic background have a greater risk of developing prostate cancer. Some people with hormone-relapsed metastatic prostate cancer are also trans.
--

The committee noted that differences in incidence and prevalence cannot be addressed in a technology appraisal. Because its recommendation does not restrict access to treatment for some people over others, the committee concluded that these were not potential equalities issues.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

N/A

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, see response above.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, see response above.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Equality considerations and explanations have been included in the draft guidance

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, see section 3.18

Approved by Associate Director (name): ...Richard Diaz.....

Date: 19 Aug 2025